Ambrobene tab 30mg 20 pc


Ambrobene tab 30mg 20 pc


SKU: 343052291 Categories: , , Tags: ,


Active substance:
1 tablet contains: active substance ambroxol hydrochloride 30.00 mg ;.
Lactose monohydrate 169.46 mg Corn starch 36.33 mg Magnesium stearate 2.41 mg Colloidal anhydrous silica 1.80 mg.
Round dvoyakovypukpye pills of white color, with a dividing line on one side and the other side is smooth.
Product form:
Tablets 30 mg.
10 tablets in blister PVC / AI-foil.
2 or 5 blisters with instructions for use placed in a cardboard box.
Hypersensitivity to ambroxol or one of the excipients; Use in children under 6 years; Pregnancy (| trimester); lactose intolerance, lactase deficiency or glucose-galactose malabsorption.
Violation of motor function and increased bronchial mucus formation (the syndrome immotile cilia), gastric ulcer and duodenum 12 in exacerbation, pregnancy (|| – ||| trimester), lactation. Patients with impaired renal function or severe liver disease must take special care with Ambrobene observing long intervals between meals or taking a drug at a lower dose.
30 mg
Acute and chronic respiratory diseases, accompanied by the formation and violation of expectoration.
Signs of toxicity in overdose of ambroxol is not revealed. There is evidence of nervous agitation and diarrhea. Ambroxol well tolerated when administered at a dose of 25 mg / kg / day. In case of severe overdosing possible increased salivation, nausea, vomiting, decreased blood pressure.
Methods intensive therapy such as vomiting, gastric lavage, should be used only in severe cases of overdose, the first 1-2 hours after ingestion. Displaying sympathetic treatment.
pharmachologic effect
Pharmacological group:
Expectorant mucolytic agent.
Ambroxol is a benzylamine – bromhexine metabolite. Differs from bromhexine absence blizzard group and hydroxyl group in the presence of p-trans cyclohexyl ring. It has secretomotoric, sekretoliticheskim and expectorant effects. After ingestion effect occurs after 30 minutes and lasts for 6-12 hours (depending on the dose). Preclinical studies have shown that ambroxol stimulates serous cells of glands of bronchial mucosa. By activating cells of ciliary epithelium and reducing the viscosity of sputum, improves mucociliary transport. Ambroxol activates the formation of surfactant by providing a direct impact on the alveolar pneumocytes type 2 and Clara cells of the small airways. Research in cell cultures and in vivo studies on animals have shown that ambroxol stimulates the production and secretion of the substance (surfactant), active on the surface of the alveoli and bronchi embryo and adult. Also in preclinical studies it has been proven antioxidant effect of ambroxol. Ambroxol, when used together with an antibiotic (amoxicillin, cefuroxime, erythromycin and doxycycline) increases their concentration in the sputum and bronchial secretions.
If ingestion ambroksol almost completely absorbed from the gastrointestinal tract. The maximum concentration is achieved 1-3 hours after ingestion. Due presystemic metabolism ambroxol absolute bioavailability after ingestion decreases by about 1/3. Formed in connection with the metabolites (such as dibromoantranilovaya acid, glucuronides) are eliminated by the kidneys. Plasma protein binding is approximately 85% (80-90%). Plasma half-life is from 7 to 12 hours. Summary half-life of ambroxol and its metabolites is about 22 hours. Excreted mainly by the kidneys as metabolites – 90%, less than 10% is excreted unchanged. Considering the high bond to plasma proteins, large volume of distribution and slow redistribution from tissues into the bloodstream, with substantial elimination of ambroxol diathesis or forced diuresis occurs. In patients with severe liver disease ambroxol clearance is reduced by 20-40%. In patients with severely impaired renal function, the half-life of metabolites of ambroxol increases. Ambroxol penetrates into cerebrospinal fluid and the placenta, and is released into breast milk.
Pregnancy and breast-feeding
Insufficient data on the use of ambroxol in pregnancy. In particular, this applies to the first 28 weeks of pregnancy. Studies conducted on animals revealed no teratogenic effect.
Application Ambrobene during pregnancy (|| – ||| trimester) can only be prescribed by a doctor, after careful assessment of risk / benefit ratio.
Studies conducted on animals have shown that ambroxol passes into breast milk. Due to the insufficient study of the drug in women during lactation, the use Ambrobene possible only on prescription, after a careful assessment of risk / benefit ratio.
Conditions of supply of pharmacies
Without recipe.
side effects
General disorders:
Rarely (from> 0.1% to
Very rarely (
On the part of the gastrointestinal tract:
Rarely (from> 0.1% to
Rarely (from> 0.1% to
special instructions
It should not be combined with antitussive drugs that prevent removal of sputum.
Very rarely the application Ambrobene skin reactions were observed in the severe form, such as Stevens-Johnson syndrome and Payepla. If you change the skin or mucous membranes, you must consult your doctor immediately and stop taking the drug.
Effects on ability to drive vehicles and management of machines and mechanisms so far not known.
Storage conditions
Store at a temperature not higher than 25 C.
Keep out of the reach of children!.
Dosing and Administration
The tablets should be swallowed whole without chewing, after eating, drinking plenty of fluids.
Children from 6 to 12 years: 1/2 tablet 2-3 times a day (15 mg ambroxol 2-3 times a day).
Adults and children from 12 years: In the first 2-3 days of treatment should take 1 tablet 3 times a day (30 mg ambroxol 3 times a day). In treatment failure adults can increase a dose of 2 tablets 2 times daily (120 mg per day of ambroxol). In the following days should take 1 tablet 2 times a day (30 mg ambroxol 2 times a day).
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist

Additional information

Weight0.100 kg


There are no reviews yet.

Add your review